NRSN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 120725 min ago

@ $1.320

Wydano: 14 vas. 2024 @ 19:31

Zwrot: -3.03%

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 16:34):

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases...

Stats
Dzisiejszy wolumen	6 610.00
Średni wolumen	296 931
Kapitalizacja rynkowa	22.19M
EPS	$0 ( 2024-04-04 )
Następna data zysków	( $-0.190 ) 2024-05-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.540
ATR14	$0.00700 (0.55%)

Wolumen Korelacja

Długi: -0.15 (neutral)

Krótki: 0.60 (weak)

Signal:(53.903) Neutral

NeuroSense Therapeutics Korelacja

10 Najbardziej pozytywne korelacje
TARA	0.944
BNIXU	0.931
CREX	0.931
VSMV	0.925
KYMR	0.924
UNCY	0.921
NICE	0.919
KNSL	0.917
MRUS	0.913
LECO	0.913

10 Najbardziej negatywne korelacje
DSWL	-0.892
CRCT	-0.892
RTPY	-0.885
OSTK	-0.882
BLKB	-0.881
SGML	-0.878
SRNGW	-0.878
DPRO	-0.875
BIOL	-0.872
BSGM	-0.871

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NeuroSense Therapeutics Korelacja - Waluta/Towar

-0.40
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.45
( neutral )

0.15
( neutral )

-0.72
( moderate negative )

NeuroSense Therapeutics Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2023
Przychody:	$0
Zysk brutto:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2022
Przychody:	$0
Zysk brutto:	$-89 000.00 (0.00 %)
EPS:	$-0.970

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.